SCHEMBL5136940

SCHEMBL5136940

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
GNRHR P30968 11/20 0.41
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
BCHE P06276 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136551 0.94 C5AR1 (0.41) C5AR1GNRHRTSHRKDM4EALDH1A1
SCHEMBL4769336 0.92 C5AR1 (0.43) C5AR1GNRHRTP53MAPTSMN1; SMN2
SCHEMBL5136299 0.92 C5AR1 (0.45) C5AR1GNRHRTP53SMN1; SMN2TSHR
SCHEMBL651365 0.92 C5AR1 (0.46) C5AR1TP53MAPTSMN1; SMN2TSHR
SCHEMBL5136710 0.91 C5AR1 (0.42) C5AR1GNRHRMAPTTSHRKDM4E
SCHEMBL5165790 0.91 GNRHR (0.46) C5AR1GNRHRTSHRKDM4EALDH1A1
SCHEMBL649626 0.91 C5AR1 (0.41) C5AR1GNRHRTP53MAPTSMN1; SMN2
SCHEMBL5136679 0.91 C5AR1 (0.44) C5AR1TP53MAPTSMN1; SMN2TSHR
SCHEMBL5072205 0.91 C5AR1 (0.46) C5AR1TP53MAPTSMN1; SMN2TSHR
SCHEMBL5134673 0.90 C5AR1 (0.43) C5AR1TP53MAPTSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed